Shenzhou Cell Company disclosed that the two -valent vaccine of the coronary disease -reorganized protein developed by it recently officially started in vaccination in Beijing.This is China's first overall -spectrum multi -price vaccine for the mutant strain.
According to the Beijing Daily client news, early December last year, the two -valent protein dual vaccine of Shenzhou cells could be approved for emergency use.The plan is recommended.
The relevant person in charge of Shenzhou cells introduced outside that Anno has been shipped at present, and has successively arrived in the districts and counties and in vaccination units in Beijing. Citizens who meet the conditions of vaccination can consult the nearby vaccination point and make an appointment for vaccination.
The public account of the Beijing Economic Development Zone "Beijing Yizhuang" news, the two vaccination points in the open area are based on the type of the original four new coronary virus vaccine types., An Nuoneng.
"This vaccine room temperature can be stored for more than six months, which is convenient for transportation to rural and underdeveloped areas and countries." Xie Liangzhi, founder of Shenzhou cellsTrimorean nanoparticles antigen, and add more advanced new water -based oil -coated oil fabric agent than traditional aluminum agent, which can enhance the antibody response, but also stimulate a strong T -cell immune response.The death rate is of great significance.
It is reported that Anno was the first large -scale vaccine for the crown disease in China for mutant strains in China.In the prestigious animal models and clinical human trials, Anno can induce the average, high neutral and antibody titration to virus variables Alpha, Beta, Delta, and OMICRON.
A third phase of clinical studies disclosed in Shenzhou cells in the UAE show that in response to the study of the Omikon BA.1 and BA.5 mutant strains, the study of the Pfizer MRNA vaccine has reached a head -up study reached the head of the MRNA vaccine.The preset non -inferiority end, that is, immunogenicity is roughly comparable to the mRNA vaccine.Compared with the MRNA vaccine, Anno can still have advantages in safety, thermal stability, storage and transportation.Clinical data shows that the incidence of local and systemic systemic side -by -side reactions is low, and it is mainly a light reaction of level 1 to 2.
The clinical study of the third phase of foreign countries shows that in order to enhance the preface of the background of the livelihood, for the Omikon BA.1 and BA.5 mutant strains, the inoculation of Anno can be induced after 28 days later.The virus neutralized antibody titration reaches 19.4 times and 15.9 times of the baseline, respectively, reaching excellent efficiency standards.
At present, Shenzhou cells have also been prepared in terms of industrialization. The annual production capacity of raw liquids is as high as billions of doses, which can provide continuous and stable vaccine supply.In order to accelerate the popularization of vaccines, Shenzhou cells have also reached a strategic cooperation agreement with Shanghai Pharmacy, which is responsible for the sales of most provinces and cities by the latter.After Beijing, Anno will also take over in other provinces across the country.
